Das Klinikum

Prof. Hans-Georg Rammensee

Prof. Hans-Georg Rammensee

Seniorprofessor

Kontakt

Telefonnummer: 07071 29-87628

E-Mail-Adresse: rammensee@uni-tuebingen.de

Klinik / Institut / Zentrum

  • Professor Dr. Hans-Georg Rammensee took up his studies of biology at the Eberhard Karls University in Tübingen in 1974. In 1982 he completed his PhD at the Max Planck Institute for Biology in Tübingen in the group of Professor Dr. Jan Klein. Following his postdoctoral studies at the Scripps Institute in La Jolla and at the Basel Institute of Immunology, he again joined the Max Planck Institute for Biology where he was group leader of the laboratory of immunology from 1987 to 1993. During this time, he also assumed teaching responsibilities at the University of Tübingen. From 1993 to 1996 he was Head of the Department of Tumor-Virus Immunology at the German Cancer Research Center (DKFZ), and was also Professor at the University of Heidelberg. From 1996 to 2023 he was Head of the Department of Immunology at the University of Tübingen. He was chair of the SFB 685 (Collaborative Research Centre) from 2005 until 2017, and deputy site coordinator of the German Consortium for Translational Cancer Research (DKTK), and co-chair of the Excellence Cluster 2180, iFIT. Now he is senior professor at the Institute for Immunology. Professor Rammensee is author of more than 400 articles, many of which have been published in top international journals including Nature, Cell and Science. For many years he has also been co-editor of several journals including Immunogenetics, Cellular and Molecular Life Science, European Journal of Immunology and others. Professor Rammensee’s work on MHC molecules and associated peptides is perceived to be a milestone in the history of immunology. Currently, he is dedicated to furthering the development of individualized cancer immunotherapy.

  • 1982-2025Since 2023 Emeritus, Senior Professorship, Institute of Immunology, University of Tübingen, Germany 2019 – 2023 Co-Chair of the Cluster of Excellence 2180 "Image-guided and Functionally Instructed Tumor Therapies" (iFIT) 2012 – 2021 Deputy site coordinator of the German Consortium for Translational Cancer Research (DKTK) and overall coordinator of the DKTK research program Cancer Immunotherapy 2006 – 2010 Panel member of the Scientific Council of the European Research Council 2005 – 2017 Chairman of the SFB 685: Immunotherapy: Molecular basis and clinical application 2004 EMBO member 2002 – 2012 Chairman of the Graduiertenkolleg 794: Graduate School for Cellular Mechanisms of Immune-associated Processes 2002 – 2004 Research Dean of the Faculty of Medicine, Tübingen 2000 Co-founder of the biotechnology enterprises immatics GmbH and Curevac GmbH 1997 – 2004 Vice-Chairman and Chairman of the Collaborative Research Center 510: Hemopoietic Stem Cell Biology and Antigen Processing, University of Tübingen 1996 – 2023 Chair, Department of Immunology (Full Professor, C4), Institute of Cell Biology, University of Tübingen, Germany 1993 – 1996 Head of Department, Tumor-Virus-Immunology Section, German Cancer Research Center (DKFZ), Heidelberg; appointment as Professor, University of Heidelberg 1987 – 1993 Group leader at the Department of Immunogenetics, Max Planck Institute for Biology, Tübingen, Germany 1985 – 1987 Scientific Member of the Basel Institute for Immunology 1982 – 1985 Postdoctoral research fellow in the laboratory of Michael J. Bevan, PhD, at Scripps Clinic and Research Institute, La Jolla, CA, USA
  • 2025 Friedrich-List-Medaille of the Industrie-und Handelskammer Reutlingen 2023 Joachim Kalden Lecture at the FAU Erlangen 2023 CIMT Lifetime Achievement Award 2022 Mitglied, Nationale Akademie der Wissenschaften Leopoldina 2020 Landesforschungspreis Baden-Württemberg 2018 Award: Exzellenter Technologietransfer Neckar-Alb 2018 der Industrie-und Handelskammer Reutlingen 2016 Jung Prize for Medicine 2016 Wilhelm Warner - Preis 2013 German Cancer Aid Award 2014 Advanced Grant, European Research Council (ERC) 2013 The Hansen Family Award, Bayer Science and Education Foundation 2008 Ceppellini Lecture of the European Federation of Immunogenetics 2006 Mitglied, Akademie der Wissenschaften und Literatur, Mainz 1997 Rose Payne Distinguished Scientist Award 1996 Paul Ehrlich und Ludwig Darmstaedter Prize 1993 Robert Koch Prize 1992 Avery Landsteiner Prize 1992 Gottfried Wilhelm Leibniz Prize 1991 Wilhelm und Maria Meyenburg Prize 1988 Heinz-Maier-Leibnitz Prize
  • 1. Falk, K., Rotzschke, O., Stevanovic, S., Jung, G., and Rammensee, H.G. (1991). Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 351, 290-296. 10.1038/351290a0. 2. Rammensee, H., Bachmann, J., Emmerich, N.P., Bachor, O.A., and Stevanovic, S. (1999). SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50, 213-219. 10.1007/s002510050595. 3. Rammensee, H.G., Wiesmuller, K.H., Chandran, P.A., Zelba, H., Rusch, E., Gouttefangeas, C., Kowalewski, D.J., Di Marco, M., Haen, S.P., Walz, J.S., et al. (2019). A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer. J Immunother Cancer 7, 307. 10.1186/s40425-019-0796-5. 4. Rammensee, H.G., Falk, K., and Rotzschke, O. (1993). Peptides naturally presented by MHC class I molecules. Annu Rev Immunol 11, 213-244. 10.1146/annurev.iy.11.040193.001241. 5. Heitmann, J.S., Tandler, C., Marconato, M., Nelde, A., Habibzada, T., Rittig, S.M., Tegeler, C.M., Maringer, Y., Jaeger, S.U., Denk, M., et al. (2023). Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency. Nat Commun 14, 5032. 10.1038/s41467-023-40758-0.
  • Publikationen